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Abstract:		1	
Background:	Patients	with	renal	disease	are	less	likely	to	undergo	percutaneous	coronary	2	
intervention	(PCI)	due	to	concerns	about	poor	outcomes.			3	
	4	
Aim:		We	describe	outcomes	following	PCI	in	individuals	with	chronic	kidney	disease	(CKD),	as	5	
compared	with	matched	controls	with	comparable	CKD	who	did	not	undergo	PCI.		We	also	identified	6	
factors	predictive	of	poor	outcomes	following	PCI	amongst	patients	with	CKD.		7	
	8	
Design:		Retrospective	observational	case-control	study.	9	
	10	
Methods:		Cases	were	individuals	with	CKD	(stages	1-5)	undergoing	PCI	between	2008-2014.		11	
Controls	were	age,	gender	and	creatinine	matched	individuals	not	requiring	PCI.		We	compared	12	
mortality	between	groups	using	Kaplan	Meier	curves	and	Cox	regression	modelling.		We	assessed	13	
changes	in	serum	creatinine	using	Wilcoxon	Rank	testing.			We	explored	the	relationship	between	14	
biochemical	and	haematological	measures	(baseline	creatinine,	calcium,	phosphate,	calcium-15	
phosphate	product,	parathyroid	hormone,	white	cell	count,	haemoglobin,	platelet	count,	c-reactive	16	
protein,	total	cholesterol)	and	post-PCI	mortality,	using	logistic	regression.	17	
	18	
Results:		We	identified	144	cases	and	144	controls.		Mortality	was	significantly	lower	amongst	cases	19	
compared	with	controls	(hazard	ratio	0.46	(95%	confidence	intervals	0.31,0.69)).		PCI	did	not	result	20	
in	a	significant	change	in	renal	function	(p=0.52).	Amongst	cases,	serum	creatinine	and	calcium-21	
phosphate	product	were	predictors	of	mortality	following	PCI.		22	
	 	 	23	
Conclusion:	Cases	undergoing	PCI	had	lower	mortality,	and	PCI	was	not	associated	with	accelerated	24	
CKD	progression.	On	this	data,	PCI	should	not	be	deferred	as	a	treatment	option	in	patients	with	25	
	 3	
CKD.		Serum	creatinine	and	calcium-phosphate	product	predict	mortality	following	PCI	in	this	cohort,	1	
and	may	be	useful	in	risk-stratifying	patients	with	CKD	being	considered	for	PCI.			2	
	 	3	
	 4	
Background:	1	
Cardiovascular	disease	is	one	of	the	leading	causes	of	mortality	in	patients	with	chronic	kidney	2	
disease	(CKD)1-4.		Cardiovascular	mortality	is	10-20	times	more	common	in	patients	with	CKD	Stage	5	3	
who	are	on	dialysis,	compared	with	the	background	population2.		Furthermore,	there	is	evidence	to	4	
suggest	that	cardiovascular	disease	typically	occurs	at	an	earlier	age,	and	follows	a	more	accelerated	5	
course	in	patients	with	CKD,	as	compared	with	the	background	population5,6.		Unlike	in	the	6	
background	population,	cardiovascular	disease	is	not	typically	the	result	of	progressive	7	
atherosclerosis,	but	instead	is	due	to	dysregulation	of	calcium	and	phosphate	homeostasis,	and	the	8	
development	of	medial	vascular	calcification7-9.		9	
	10	
There	is	no	consensus	regarding	how	best	to	manage	cardiovascular	disease	in	patients	with	CKD.		11	
Most	trials	of	treatments	for	cardiovascular	disease	exclude	patients	with	renal	disease,	and	as	such	12	
the	evidence	base	underpinning	the	management	of	these	patients’	cardiovascular	disease	is	13	
sparse10,11.		In	practice,	patients	with	CKD	are	less	likely	to	receive	medications	such	as	Aspirin,	ACE	14	
inhibitors	and	Beta	blockers,	due	to	concerns	about	side	effects/toxicity	and	adverse	effects	on	renal	15	
function10,12.		In	addition,	patients	with	CKD	are	less	likely	to	be	offered	angiography	and	or	16	
percutaneous	coronary	intervention	(PCI)12.		This	is	in	part	a	reflection	of	the	fact	that	renal	17	
impairment	predicts	poorer	outcomes	including	mortality	and	procedural	complications	such	as	18	
bleeding	and	in-stent	stenosis	following	PCI12-15.		Furthermore,	many	clinicians	are	concerned	that	19	
the	contrast	load	associated	with	angiography	can	lead	to	an	accelerated	loss	of	renal	function	and	20	
an	earlier	need	for	renal	replacement	therapy16,18.			21	
	22	
Whilst	many	studies	have	explored	outcomes	following	PCI	for	patients	with	CKD	compared	with	23	
patients	with	normal	renal	function,	few	have	compared	outcomes	for	patients	with	CKD	undergoing	24	
PCI	and	those	with	comparable	CKD	not	requiring	PCI13,14,19,20.		As	such,	it	is	unclear	whether	the	poor	25	
	 5	
outcomes	previously	described	amongst	patients	with	renal	disease	undergoing	PCI	are	a	result	of	1	
the	PCI,	or	simply	a	marker	of	the	high	degree	of	morbidity	and	mortality	associated	with	CKD	itself.	2	
	3	
This	study	aimed	to	describe	mortality,	cardiovascular	and	renal	outcomes	following	PCI	in	patients	4	
with	CKD,	as	compared	with	age,	sex	and	creatinine	matched	controls	who	had	not	undergone	PCI.	5	
We	also	explored	the	relationship	between	baseline	biochemistry	and	haematology	results	and	6	
mortality	following	PCI.		In	particular,	we	explored	whether	serum	measurements	of	calcium,	7	
phosphate	and/or	calcium-phosphate	product	are	useful	predictors	of	mortality	amongst	this	8	
cohort,	as	dysregulation	of	calcium	and	phosphate	metabolism	is	thought	to	be	the	main	reason	for	9	
the	medial	vascular	calcification	that	drives	excess	cardiovascular	morbidity	and	mortality	in	patients	10	
with	renal	disease.	 	11	
	 6	
Methods:	1	
Study	population:	2	
We	conducted	a	retrospective	case-control	study.		Cases	were	individuals	who	had	undergone	3	
percutaneous	coronary	intervention	between	1st	January	2008	and	31st	December	2014,	and	who	4	
were	known	to	the	nephrology	team	at	the	time	of	intervention.		Cases	were	identified	by	cross-5	
checking	all	individuals	who	underwent	PCI	in	a	tertiary	cardiology	centre	(University	Hospital	of	6	
Wales)	during	the	study	period,	with	a	database	of	patients	receiving	care	under	a	nephrology	7	
service	(Vital	Data).		Controls	were	individuals	receiving	care	from	nephrology	services	who	had	not	8	
undergone	percutaneous	coronary	intervention.		Controls	were	age,	gender	and	creatinine	matched.		9	
For	individuals	who	underwent	PCI,	the	indication	for	PCI,	number	of	vessels	treated,	and	location	of	10	
lesions	treated	were	documented.		Data	regarding	left	ventricular	function	was	not	available	in	this	11	
retrospective	study.		To	minimise	the	risk	of	contrast	induced	nephropathy,	the	lowest	volume	of	12	
low	osmolar	contrast	agent	was	used	for	all	individuals	who	underwent	PCI,	in	line	with	current	13	
guidelines21.	We	compared	outcomes	for	cases	and	controls.	14	
	15	
Outcomes:	16	
Cases	were	followed	up	from	the	time	of	PCI	to	the	end	of	the	data	collection	period	(1st	July	2016)	17	
or	until	the	time	of	death.		Controls	were	followed	up	from	the	date	of	the	blood	test	upon	which	18	
age	and	creatinine-based	matching	was	based	until	the	end	of	the	data	collection	period	(1st	July	19	
2016)	or	until	the	time	of	death.	20	
	21	
The	primary	outcome	was	mortality	at	the	end	of	follow	up.		We	also	collected	data	regarding	22	
changes	in	serum	creatinine	following	PCI,	to	ascertain	whether	PCI	was	associated	with	acceleration	23	
in	the	progression	of	CKD	in	the	long	term.		We	identified	cases	of	contrast	induced	nephropathy	24	
using	the	recognised	definition	of	a	relative	(>25%)	or	absolute	(≥44	µmol/l)	increase	in	serum	25	
	 7	
creatinine	from	the	baseline	value	within	the	first	48-72hours	following	percutaneous	coronary	1	
intervention22.		2	
	3	
We	also	collected	data	on	cardiovascular	outcomes	amongst	cases.		Specifically,	we	documented	4	
whether	they	had	experienced	recurrent	angina;	an	acute	coronary	syndrome;	symptomatic	heart	5	
failure,	or	if	they	required	further	angiography/PCI	prior	to	the	end	of	the	follow	up	period.	6	
	 	7	
	 8	
Secondary	analysis:	1	
We	collected	data	regarding	baseline	creatinine,	calcium,	phosphate,	calcium-phosphate	product,	2	
parathyroid	hormone,	white	cell	count,	haemoglobin,	platelet	count,	c-reactive	protein,	and	total	3	
cholesterol	for	all	cases.		Baseline	measures	were	defined	as	the	mean	value	of	all	results	during	the	4	
3	months	preceding	PCI.		We	explored	the	relationship	between	these	variables	and	mortality.	5	
	6	
Statistical	methods:	7	
Survival	time	was	compared	between	cases	and	controls	using	Kaplan	Meier	survival	curves.		Cox	8	
regression	modelling	was	subsequently	used	to	obtain	an	adjusted	hazard	ratios	(aHR)	with	95%	9	
confidence	intervals.		Data	were	right	censored	at	the	end	date	of	the	follow	up	period	for	patients	10	
who	remained	alive.	11	
	12	
For	cases,	we	used	a	Wilcoxon	rank	test	to	compare	serum	creatinine	at	baseline	with	serum	13	
creatinine	at	the	end	of	the	follow	up	period	(due	to	the	non-parametric	distribution	of	the	data).		14	
The	proportion	of	cases	experiencing	adverse	cardiovascular	outcomes	were	described.	15	
	16	
Logistic	regression	modelling	was	used	to	explore	the	relationship	between	the	baseline	17	
haematology	and	biochemistry	results	of	cases	and	mortality	following	PCI.		Estimates	of	effects	18	
between	cases	and	controls	are	reported	as	crude	odds	ratios	(ORs)	and	adjusted	ORs	(aORs)	19	
alongside	95%	confidence	intervals.	Adjusted	odd	ratios	were	derived	after	adjusting	for	age,	gender	20	
and	baseline	creatinine	as	appropriate.	21	
	22	
Ethics	and	Information	Governance:	Patient	data	and	outcomes	were	retrieved	from	internal	23	
databases.		This	work	represents	an	audit	of	outcomes	in	our	department,	and	as	such	ethical	24	
approval	was	not	required.	25	
	26	
	 9	
Data	analyses	were	carried	out	using	IBM	SPSS	Statistics	version	22	and	Stata	version	14.	 	1	
	 10	
Results:	1	
We	identified	144	patients	who	underwent	PCI	between	1st	January	2008	and	31st	December	2014,	2	
who	were	known	to	the	nephrology	team	at	the	time	of	intervention.	144	age,	gender	and	creatinine	3	
matched	controls	were	identified.		The	mean	follow-up	period	was	42.2	months	for	cases	(range	1-4	
100	months)	and	36.0	months	for	controls	(range	0-87	months.)	5	
	6	
Baseline	characteristics	are	described	in	table	1.		Characteristics	were	similar	for	cases	and	controls,	7	
indicating	appropriate	matching	of	cases	to	controls.		Indications	for	percutaneous	coronary	8	
intervention	amongst	cases	are	described	in	table	2a.		The	commonest	indication	for	PCI	was	acute	9	
coronary	syndrome,	followed	by	angina.	A	small	proportion	of	cases	underwent	elective	angiography	10	
and	percutaneous	coronary	intervention	in	the	absence	of	any	symptoms	or	signs	of	coronary	11	
ischaemia,	as	part	of	the	routine	work	up	for	renal	transplantation	and	subsequent	demonstration	of	12	
ischaemia.	13	
	14	
The	cases	included	106	patients	treated	for	single	vessel	coronary	artery	disease,	35	patients	with	2	15	
vessel	disease	and	1	with	3	vessel	disease	(table	2b).		Lesions	treated	were	located	in	the	right	16	
coronary	artery	lesions	in	60	cases,	the	left	circumflex	in	17	cases	and	the	left	anterior	descending	17	
artery	in	51	cases,	and	the	left	main	stem	vessels	in	4	cases	(table	2c).		The	remainder	of	treated	18	
lesions	related	to	side	branch	disease	involving	either	large	diagonal	vessel	or	obtuse	marginals.	19	
	20	
PCI	was	associated	with	lower	mortality	compared	to	the	non-PCI	matched	control	group.		Mortality	21	
was	high	in	both	groups	(28%	at	the	end	of	follow	up	in	cases,	and	55%	at	the	end	of	follow	up	22	
amongst	controls).		Time	to	mortality	was	lower	amongst	the	control	group,	and	this	was	statistically	23	
significant	(hazard	ratio	0.46	(0.31,	0.69))	(figure	1.)	24	
	25	
	 11	
PCI	did	not	lead	to	long-term	deterioration	in	renal	function.		There	was	no	statistically	significant	1	
change	in	creatinine	amongst	cases	following	percutaneous	coronary	intervention	(mean	creatinine	2	
prior	to	intervention	=	198	micromol/L,	mean	creatinine	at	the	end	of	follow	up	=196	micromol/L,	3	
p=0.52.)			4	
	5	
Data	regarding	contrast	induced	nephropathy	was	available	for	88	(61%)	of	cases,	of	whom	9	6	
(10.2%)	met	the	criteria	for	a	diagnosis	of	contrast	induced	nephropathy.		7	
	8	
Cardiac	outcomes	for	cases	are	described	in	table	2b.		Most	patients	had	a	favourable	outcome.		9	
82%	remained	free	of	symptomatic	cardiovascular	disease	at	the	end	of	the	follow	up	period.		The	10	
commonest	adverse	cardiovascular	outcome	was	a	recurrence	of	angina,	affecting	19%	of	patients.		11	
	12	
Univariate	analysis	revealed	increased	age,	calcium,	phosphate,	and	calcium-phosphate	product	to	13	
be	associated	with	a	statistically	significant	increased	risk	of	mortality	amongst	cases.		Increased	14	
haemoglobin	was	associated	with	a	lower	risk	of	mortality	(table	3).		15	
	16	
After	adjusting	for	age	and	gender,	an	increased	creatinine	continued	to	be	associated	with	17	
increased	mortality	after	PCI	(p=0.003.)	After	adjusting	for	age,	gender	and	creatinine,	serum	18	
phosphate	and	haemoglobin	were	no	longer	significantly	associated	with	mortality.		However,	19	
calcium-phosphate	product	was	still	significantly	associated	with	an	increased	mortality	(p=0.04)	20	
(table	3).	21	
22	
	 12	
Discussion	1	
Our	results	confirm	that	mortality	is	high	amongst	patients	with	CKD,	as	would	be	expected	from	the	2	
results	of	previously	published	studies23,24.	Whilst	studies	have	previously	demonstrated	high	3	
mortality	amongst	patients	with	CKD	undergoing	PCI	as	compared	with	individuals	with	normal	renal	4	
function	undergoing	PCI,	it	is	unclear	whether	the	excess	mortality	is	a	result	of	PCI,	or	whether	it	5	
reflects	the	high	levels	of	mortality	associated	with	renal	disease	itself.		In	order	to	elucidate	this,	it	6	
is	necessary	to	compare	outcomes	between	individuals	with	renal	disease	undergoing	PCI,	and	7	
individuals	with	comparable	CKD	not	requiring	PCI.		Our	study	used	a	case-control	approach	to	8	
compare	outcomes	between	individuals	with	renal	disease	undergoing	PCI	and	creatinine-matched	9	
controls	who	did	not	undergo	PCI.	10	
	11	
The	first	key	finding	from	our	study	is	that	patients	with	renal	disease	who	underwent	PCI	had	lower	12	
mortality	than	creatinine-matched	controls.		This	data	would	suggest	that	PCI	may	protect	against	13	
short	term	mortality	in	a	cohort	of	patients	with	renal	disease.			This	is	in-keeping	with	the	findings	14	
of	a	previously	published	systematic	review	which	concluded	that	early	angiography	and/or	PCI	15	
conferred	a	survival	benefit,	at	least	in	those	with	early-moderate	CKD25.	We	therefore	suggest	that	16	
the	excess	of	mortality	following	PCI	previously	documented	amongst	patients	with	renal	disease	is	17	
likely	to	reflect	the	poor	prognosis	associated	with	having	renal	disease	in	itself,	rather	than	being	18	
directly	related	to	the	PCI	procedure.		19	
	20	
In	addition	to	the	perceived	high	rates	of	mortality	amongst	CKD	patients	undergoing	PCI,	many	21	
clinicians	have	expressed	concern	that	PCI	may	lead	to	an	accelerated	loss	of	renal	function	amongst	22	
patients	with	CKD	as	a	result	of	the	contrast	burden	associated	with	the	procedure16,18.		The	concern	23	
that	PCI	may	hasten	time	to	end	stage	renal	failure	and	the	need	for	renal	replacement	therapy	has	24	
contributed	to	the	reluctance	to	offer	PCI	to	many	patients	with	renal	disease12.	10.2%	of	cases	25	
developed	contrast	induced	nephropathy,	which	is	comparable	with	the	incidence	of	contrast	26	
	 13	
induced	nephropathy	in	previously	published	studies26,27.		Importantly	we	did	not	observe	an	1	
accelerated	rate	of	decline	in	renal	function	in	the	long-term	following	PCI	amongst	our	cases.			2	
Whilst	one	of	the	limitations	of	this	study	is	the	relatively	short	follow	up	period	(mean	42.24	3	
months,	range	1-100	months),	deteriorating	renal	function	as	a	direct	result	of	PCI	is	usually	due	to	4	
an	acute	effect	of	contrast	and	associated	acute	kidney	injury,	and	would	have	been	apparent	during	5	
this	period	of	follow	up16,18.			6	
	7	
Since	our	data	suggests	that	PCI	confers	a	survival	advantage	in	this	group,	and	is	not	associated	with	8	
an	accelerated	decline	in	renal	function	amongst	patients	with	CKD,	we	suggest	that	having	CKD	in	9	
itself	should	not	be	considered	a	contraindication	to	PCI.		Furthermore,	since	patients	with	renal	10	
disease	have	high	mortality	rates	independently	of	the	need	for	coronary	revascularisation,	much	of	11	
the	focus	of	care	for	patients	with	progressive	renal	disease	is	on	trying	to	maximise	quality	of	life	12	
and	minimise	distressing	symptoms23,24.		Amongst	our	cohort,	81%	did	not	experience	recurrent	13	
angina	during	the	follow	up	period,	thereby	suggesting	PCI	had	a	positive	impact	on	their	symptom	14	
profile,	at	least	in	the	short	term.		We	therefore	believe	that	PCI	is	a	treatment	that	has	the	potential	15	
to	dramatically	improve	quality	of	life	in	patients	with	renal	disease,	without	accelerating	the	16	
progression	of	their	underlying	renal	disease.	17	
	 	18	
We	recognise	that	our	case	mix	includes	patients	with	a	broad	spectrum	of	renal	disease.		We	19	
therefore	sought	to	identify	factors	associated	with	an	increased	risk	of	mortality	amongst	our	cases.		20	
As	expected,	we	found	that	increased	creatinine	was	associated	with	a	higher	mortality	post	21	
procedure,	independently	of	age	and	gender.		Similarly,	a	high	serum	phosphate	and	low	serum	22	
haemoglobin,	both	of	which	are	markers	of	severe	renal	disease,	were	significantly	associated	with	23	
higher	mortality.		After	correcting	for	creatinine,	neither	remained	significantly	associated	with	24	
mortality,	illustrating	the	fact	that	they	act	as	surrogate	markers	of	the	severity	of	renal	disease	in	25	
	 14	
this	setting.		These	findings	support	our	observation	that	the	severity	of	renal	disease	is	one	of	the	1	
main	predictors	of	mortality	amongst	this	cohort.	2	
	3	
The	only	biochemical	marker	that	remained	significantly	associated	with	mortality,	after	adjusting	4	
for	age,	gender	and	creatinine,	was	the	calcium-phosphate	product.	It	is	well	recognised	that	in	5	
patients	with	CKD,	the	excess	cardiovascular	mortality	is	not	due	to	the	traditional	model	of	6	
atherosclerotic	disease,	but	is	instead	a	result	of	vascular	calcification	that	occurs	secondary	to	7	
disruption	of	calcium	and	phosphate	homeostasis7-9.		Studies	have	previously	demonstrated	that	8	
calcium-phosphate	product	may	be	a	useful	tool	in	estimating	the	risk	of	mortality	and	9	
cardiovascular	disease	in	patients	with	CKD28-30.		Our	data	suggest	that	calcium-phosphate	product	10	
may	also	be	useful	in	predicting	mortality	following	PCI	in	this	group.		In	addition,	since	calcium-11	
phosphate	product	may	be	affected	by	several	modifiable	factors	such	as	diet,	the	use	of	phosphate	12	
binders	and	effective	vitamin	D	replacement,	it	is	possible	that	efforts	to	lower	calcium-phosphate	13	
product	could	lead	to	more	favourable	outcomes	in	this	group.		Further	studies	are	required	to	14	
explore	this30.	15	
	16	
Although	this	study	to	our	knowledge	is	the	first	to	compare	the	outcome	of	PCI	in	CKD	patients	17	
compared	to	an	age	matched	control	group,		a	limitation	of	this	study	is	that	the	majority	of	cases	18	
underwent	PCI	to	treat	single	vessel	disease	with	the	highest	proportion	of	treated	vessels	being	19	
RCA.		,		We	acknowledge	therefore	that	we	should	be	cautious	in	generalising	the	findings	to	20	
individuals	undergoing	PCI	for	multi	vessel	disease	who	by	definition	have	more	severe	coronary	21	
artery	disease.			and	are	likely	to	have	higher	levels	of	exposure	to	contrast	during	the	procedure.		22	
However,	our	findings	remain	relevant	to	clinical	practice,	as	data	from	the	British	Cardiovascular	23	
Intervention	Society	Adult	Interventional	Procedure	Audit	2016	demonstrate	that	nationally,	the	24	
vast	majority	of	PCI	procedures	are	undertaken	to	treat	single	vessel	disease	(77.2%	of	all	PCI)31.		25	
Whilst	in	our	study	the	commonest	location	of	lesions	treated	was	the	right	coronary	artery,	26	
	 15	
nationally	the	commonest	location	for	lesions	treated	by	PCI	is	the	left	anterior	descending	artery31.		1	
Further	studies	are	however	required	to	establish	whether	there	is	an	association	between	the	2	
location	of	lesions	treated	and	outcomes	in	patients	with	chronic	kidney	disease.	3	
	4	
Summary	5	
We	have	demonstrated	that	PCI	was	associated	with	a	reduction	in	mortality,	and	did	not	lead	to	an	6	
acceleration	in	the	progression	of	CKD	in	a	cohort	of	patients	with	CKD	compared	with	creatinine	7	
matched	controls	who	did	not	undergo	percutaneous	coronary	intervention.		We	therefore	suggest	8	
that	CKD	in	itself	should	not	be	considered	a	contraindication	to	PCI.		The	decision	to	undertake	PCI	9	
should	be	considered	on	an	individual	patient	basis,	and	should	take	into	account	the	severity	of	10	
their	CKD.		Calcium-phosphate	product	may	be	a	useful	tool	in	identifying	patients	with	renal	disease	11	
who	are	at	high	risk	of	mortality	following	PCI.	 	12	
	 16	
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		 Cases	 Controls	
Age	(years)	 69	(62.0,	77.0)	 69	(61.7,	77.4)	
Creatinine	(micromol/L)	 142	(103,	206)	 142	(102,	209)	
Gender	 103	(72%)	 103	(72%)	
Diabetes	 41	(28.4%)	 45	(31.3%)	
Table	1:	Baseline	characteristics	of	cases	and	controls.		Values	are	median,	interquartile	range	(as	1	
data	was	positively	skewed).		Gender	is	described	as	the	number	and	%	of	males	in	each	group.		The	2	
number	and	%	of	individuals	with	co-existing	diabetes	are	also	described.	 	3	
	 22	
	1	
	 Proportion	of	cases		
Acute	coronary	syndrome	 86	(60%)	
Angina	 42	(29%)	
Investigation	of	heart	failure	 3	(2%)	
Pre	renal	transplant	 6	(4%)	
Ventricular	Tachycardia	of	unknown	origin	 2	(1%)	
Unknown	 5	(4%)	
Table	2a:		Indication	for	percutaneous	coronary	intervention.	2	
	 Proportion	of	cases		
Single	vessel	coronary	artery	disease	treated	 106	(74%)	
Two	vessel	disease	treated	 35	(24%)	
Triple	vessel	disease	treated	 1	(1%)	
Table	2b:		Number	of	vessels	treated.	3	
	 Proportion	of	lesions	
Right	coronary	artery	 60	(34%)	
Left	circumflex	artery	 17	(10%)	
Left	anterior	descending	artery	 51	(29%)	
Left	main	stem	vessels	 4	(2%)	
Side	branch	disease	(large	diagonal	vessel	or	obtuse	marginals)	 45	(25%)	
Table	2c:		Location	of	lesions	treated	4	
	5	
	6	
	7	
	8	
	 23	
	 Proportion	of	cases		
Death	 40	(27.8%)	
Recurrent	angina	 27	(18.8%)	
Recurrent	ACS	 14	(9.7%)	
Heart	failure	 18	(12.5%)	
Repeat	angiogram	needed	 26	(18.1%)	
Further	PCI	 23	(16%)	
Table	3:		Cardiovascular	outcomes	following	percutaneous	coronary	intervention.	 	1	
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	1	
		 Odds	Ratio		
±	95%	CI	
p	value	 Adjusted	Odds	Ratio		
±	95%	CI	
p	value	
Age	 1.60	(1.16,	2.23)	 0.01	 	 	
Gender	 0.94	(0.41,	2.11)	 0.87	 	 	
Creatinine	 1.00	(1.00,	1.01)	 0.01	 1.00	(1.00,	1.01)*	 0.003	
Calcium	 0.25	(0.01,	4.92)	 0.81	 0.78	(0.03,	20.69)**	 0.877	
Phosphate	 5.57	(1.56,	19.89)	 0.008	 6.43	(0.97,	42.64)**	 0.054	
Calcium	Phosphate	
product	
2.32	(1.24,	4.35)	 0.008	 2.34	(1.03,	5.34)**	 0.042	
PTH	 1.04	(0.99,	1.09)	 0.15	 1.04	(0.99,	1.10)**	 0.146	
Hb		 0.97	(0.94,	0.99)	 0.005	 0.98	(0.95,	1.01)**	 0.220	
WCC	 1.05	(0.90,	1.24)	 0.53	 1.08	(0.91,	1.28)**	 0.399	
Platelets	 1.00	(0.96,	1.00)	 0.89	 1.00	(1.00,	1.01)**	 0.485	
CRP		 1.00	(0.99,	1.02)	 0.62	 1.00	(0.99,	1.02)**	 0.784	
Total	Cholesterol	 1.17	(0.81,	1.70)	 0.40	 1.27	(0.84,	1.92)**	 0.267	
Table	3:	Relationship	between	baseline	biochemistry	and	haematology	results	and	mortality.		2	
Results	are	crude	and	adjusted	odds	ratios	with	95%	confidence	intervals	and	p	values	derived	from	3	
logistic	regression	models.	4	
*Adjusted	for	age	and	gender	5	
**	Adjusted	for	age,	gender,	creatinine	 	6	
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	1	
Figure	1:		Kaplan	Meier	Curves	demonstrating	time	to	mortality	(in	days)	amongst	cases	and	2	
controls.	3	
